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and arthritis of the hand or wrist (34.1%) were the most com-
monly reported. Compared with other variables, age, arthritis,
and depressive symptoms were highly associated with the SF-36
physical domains. Depressive symptoms had the strongest asso-
ciation with each of the four SF-36 mental domains. Among the
chronic conditions, the adverse impact of having difﬁculty in
controlling urination, a relatively neglected condition, was only
second to depressive symptoms in its negative relationship with
vitality, social-functioning, and mental health. CONCLUSION:
Chronic conditions were commonly reported among the older
adults. The unique associations found between chronic condi-
tions and domains of health status demonstrate the importance
of examining the burden of these conditions in terms of func-
tioning and well-being.
PIH11
THE EFFECT OF OVER-THE-COUNTER DRUG MISUSE AND
THE ASSOCIATED ADES ON HRQOL IN THE ELDERLY
Sansgiry SS, Nadkarni A, Chanda S
University of Houston, Houston,TX, USA
OBJECTIVES: To measure over-the-counter (OTC) drug misuse
in the elderly and study its relationship with health-related
quality of life (HRQOL). In addition, adverse drug events
(ADEs) due to OTC misuse and its relationship to HRQOL were
examined. METHODS: A questionnaire will be administered to
a sample of elderly patients, aged 65 and above, selected ran-
domly from those attending community wellness programs in the
Houston area. Information on OTC drug use/misuse, ADEs,
HRQOL and demographic data were obtained using a combi-
nation of self-administered questionnaire and personal interview
technique. HRQOL was measured using the SF-12v2 scale and
analyzed using the SAS statistical package at a priori set signiﬁ-
cance level of 0.05. RESULTS: A total of 157 surveys were 
collected resulting in a correct response rate of 66.53% from
four senior retirement centers. There were slightly more males
(56.21%) and Hispanic participants (67.55%) with a median age
of 74 years. Misuse occurred in 18% of the respondents and
ADEs in 23%. The mean physical (PCS) and mental (MCS) com-
ponent scores of the SF-12 scale were similar for the elderly (PCS
= 52. 53 ± 8.35, MCS = 53.99 ± 6.91). There was no signiﬁcant
difference in the occurrence of ADEs between those who did or
did not misuse OTC products. Although there was no signiﬁcant
difference in HRQOL in those who did or did not misuse OTC
products, there was a signiﬁcant difference in HRQOL between
those who experienced ADEs (PCS = 49.50 ± 6.86) and those
who did not (PCS 53.49 ± 8.21). However, the signiﬁcant effect
was predominately associated with the PCS and its domains
namely, physical functioning, role physical, and general health.
CONCLUSIONS: Understanding trends in OTC drug use and
misuse will help in devising methods to prevent ADEs and addi-
tionally improve HRQOL.
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RELATIONSHIP BETWEEN QUALITY OF LIFE AND
INAPPROPRIATE DRUG USE:A RETROSPECTIVE ANALYSIS IN
AN ELDERLY POPULATION
Jiang JZ, Franic D
University of Georgia, Athens, GA, USA
OBJECTIVES: The primary purpose of this study is to compare
two widely used generic quality of life measures, SF-12 and EQ-
5D, in differentiating between appropriate and inappropriate
prescription medication users in an elderly cohort. METHODS:
Participants 65 years or older were taken from the Medical
Expenditure Panel Survey (MEPS) panel ﬁve from January, 2000
to December, 2001. A longitudinal retrospective cohort study
was conducted. Potential appropriate and inappropriate pre-
scription medication users were identiﬁed based on updated
Beers criteria list identifying inappropriate drug use in the elderly
(Fick, 2003). National Drug Code numbers were used to iden-
tify potential inappropriate prescription drug use. The dependent
variable, quality of life was measured using self-report versions
of SF-12 (mental health, MCS, physical health, PCS and general
health score) and EQ-5D (index, EQ-5DIndex and visual ana-
logue scale score, EQ-5DVAS). Using OLS regression, health
status scores were regressed on age, gender, prescription number
and health status in the previous year. RESULTS: Of the 716 par-
ticipants aged 65 years in the dataset, 455 were identiﬁed to have
appropriate drug use in 2000. Of these, 381 and 74 met the cri-
teria for appropriate and inappropriate drug use, respectively, in
2001. Appropriate prescription drug users had higher health
status scores than inappropriate users for PCS, and EQ-5D
(index and VAS scores), at the 0.05 level. Regression analysis
reported signiﬁcant model for PCS (Adjusted R2 = 0.3032, p <
0.0001); with signiﬁcant beta weights for prescription number,
prior health status, age and inappropriate drug use (p < 0.05).
CONCLUSION: Aging population is at greater risk of adverse
health events which can signiﬁcantly affect their quality of life.
Generic measures showed higher quality of life scores for indi-
viduals with appropriate drug use over those without. Prospec-
tive studies investigating inappropriate drug use, disease speciﬁc
quality of life measures, in addition to the impact on cost are
warranted.
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COST-EFFECTIVENESS ANALYSIS OF BENIGN PROSTATIC
HYPERPLASIA (BPH) TREATMENTS
DiSantostefano R, Biddle A, Lavelle J
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: The long-term cost-effectiveness of newer treat-
ments for BPH, including transuretheral microwave thermother-
apy (TUMT) and combination medical therapy, has not been
sufﬁciently studied against existing alternatives. This study 
compared the cost-utility and cost-consequences of watchful
waiting (WW), alpha-blockers (AB), 5-alpha-reductase inhibitors
(5ARI), their combination, TUMT, and transurethral prostatec-
tomy (TURP) in men with moderate to severe BPH symptoms.
METHODS: A Markov model was constructed to estimate the
clinical consequences, costs, and incremental cost per quality-
adjusted life year (QALY) gained. Clinical consequences included
progression to TURP, adverse events, and corresponding QALYs.
Treatment costs were estimated from an insurance claims 
database and Medicare fee schedules. Treatment response and
adverse event estimates were derived from published literature.
Analyses considered a 20-year time frame, societal perspective,
different age cohorts, symptom levels, and possible treatment
switching. Cost and effectiveness were discounted at 3% per
year. RESULTS: AB was cost-effective for treating moderate
symptoms using the threshold of $50,000/QALY for most
cohorts ($15,000–26,000 per QALY relative to WW). TURP was
the most cost-effective treatment for severe symptoms relative 
to WW ($4,000–17,000 per QALY). 5ARI and combination
therapy were dominated by alternatives due to annual pharma-
ceutical costs. The cost/QALY increased with age for TUMT and
TURP and was stable for AB. Results were robust to costs, but
sensitive to probabilities, utility weights, and life expectancy.
Acceptability curves showed consistent trends for the alternatives
most likely to be cost-effective. Preliminary expected value of
perfect information (EVPI) analysis suggests additional informa-
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tion is needed on preferences and extent of improvement. CON-
CLUSIONS: AB and TURP were the most cost-effective alter-
natives for moderate and severe symptoms, respectively. TUMT
was promising for moderate symptoms, and older patients with
severe symptoms, but was dominated under many conditions.
These results have implications for future health practice with
aging of the population and rising expenditures.
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USE OF SILDENAFIL CITRATE IN NON-ADHERENT PATIENTS
WITH CVD, DIABETES OR DEPRESSION
McLaughlin T1, Harnett J2, Scott B3, Burhani S1
1NDCHealth, Phoenix, AZ, USA; 2Pﬁzer Inc, New York, NY, USA;
3NDCHealth, Westerville, OH, USA
OBJECTIVES: Patients often attribute erectile dysfunction to
comorbid medications and subsequently discontinue therapy.
This study explores the impact of sildenaﬁl citrate in patients
non-adherent with comorbid medications. METHODS: Retro-
spective cohort study using administrative claims data and cash
prescriptions (January 2002-July 2002). Identiﬁed adult male
patients with an antihypertensive (AH), antidepressant (AD),
oral hypoglycemic (OHG) or lipid-lowering (LL) prescription in
the 12 months prior to / following index sildenaﬁl prescription.
Patients with a comorbid medication possession ratio (MPR)
<0.8 prior to sildenaﬁl (i.e., non-adherent) were evaluated for
changes in days supply and MPR. RESULTS: About 60% of the
12,281 patients who initiated sildenaﬁl were previously non-
adherent with comorbid medications. Mean MPR, for all disease
cohorts and irrespective of payment source for sildenaﬁl,
increased after the index date. Compared to self-pay sildenaﬁl
patients, 3rd party sildenaﬁl patients had statistically signiﬁ-
cantly larger increases in MPR for AH, OHG and LL prescrip-
tions (range of MPR change: 8%–17%). After initiation of
sildenaﬁl, 20% (OHG) to 36% (AH) became adherent. Signiﬁ-
cantly greater increases in MPR were seen in patients with 3+
sildenaﬁl prescription claims. Cash patients were less likely to
have 3+ sildenaﬁl prescriptions vs. 3rd party patients. CON-
CLUSIONS: In patients who were previously non-adherent to
chronic medications, there appeared to be a signiﬁcant increase
in overall adherence after initiating sildenaﬁl. This increase 
was signiﬁcantly larger in patients with insurance coverage 
for sildenaﬁl, as well as in patients with increased sildenaﬁl 
utilization.
PIH15
IMPACT OF BENEFIT DESIGN ON PDE-5 UTILIZATION AND
COSTS IN A LARGE PBM DATABASE
Patel BV1, Leslie RS1, Harnett J2, Szczotka A1
1MedImpact Healthcare Systems, Inc, San Diego, CA, USA; 2Pﬁzer Inc,
New York, NY, USA
OBJECTIVES: To determine how different factors related to
beneﬁt design impact the utilization and costs of PDE-5
inhibitors including vardenaﬁl, tadalaﬁl and sildenaﬁl in adult
males. METHODS: Pharmacy claims from a large, private phar-
macy beneﬁt management company over a 2-year period from
October 1, 2002 to September 30, 2004 were analyzed. PDE-5
utilization, average of age of database population and PDE-5
users, and PMPM were evaluated. RESULTS: The average
PMPM for PDE-5 agents was $0.16 over the entire study period
with an average of 5.7 pills/rx. The average age of patients for
different beneﬁt designs ranged from 52 to 68 years while the
sample population age ranged from 24 to 48 years. Plans with
no PDE-5 agent on formulary had an average PMPM of $0.08
vs. $0.22 in those with at least one PDE-5 on formulary. Copays
for open formulary incentive plans with PDE-5’s on 2nd tier were
approximately $10 less than PDE-5s on 3rd tier while plan spon-
sored PMPM costs were similar ($0.17 vs. $0.18). This was
attributed to a lower quantity dispensed per prescription (4.5 vs.
6.9). Similar trends were found for closed formulary plans where
PDE-5s were on formulary vs. not on formulary (PMPM of
$0.03 vs. $0.02). Differences in plan sponsored PMPM costs for
open formulary, 1-tier vs. 2-tier plans were attributed to differ-
ences in member copays ($3.60 vs. $18.63) and not utilization
(6.1 vs. 6.4 pills/rx). CONCLUSION: Despite a younger overall
population, PDE-5 utilization was utilized in the 50+ age group
regardless of beneﬁt design or restrictions. Plan sponsors can
expand access to PDE-5 agents and at the same time limit their
PMPM costs with quantity limits.
PIH16
UTILIZATION PATTERNS OF SIDENAFIL CITRATE IN A
SENIOR MANAGED CARE POPULATION
Harnett J1, Broderick WC2
1Pﬁzer Inc, New York, NY, USA; 2Ingenix, Houston,TX, USA
OBJECTIVE: To analyze the utilization patterns of sidenaﬁl
citrate in a senior managed care population. METHODS: Using
a large managed care administrative claims database, all male
patients with a prescription for sidenaﬁl citrate from December
2003 through November 2004 were selected from among
patients ages 18 years and older (n = 107,879). A diagnosis for
erectile dysfunction (ED) was not required. Prevalence, age,
number of prescriptions and days supply, per senior member per
month (PSMPM) cost, concomitant medications, and cost by
diagnosis were analyzed. The PSMPM of sildenaﬁl was com-
pared with antihistamines and proton pump inhibitors (PPI’s).
RESULTS: The median age of sildenaﬁl users overall was 52
years old and overall per member per month cost was $0.16.
Patients ages 65 and older (65+) represented 11.5% of all side-
naﬁl use in the study (n = 12,383). 4.0% of eligible 65+ members
had at least one prescription for sidenaﬁl compared with 2.5%
of members younger than 65. The average age of senior silde-
naﬁl users was 69.5 years old with 62.9% of seniors between
65–69 years of age; 23.5% were 70–74, and 3.5% were 80 years
of age and older. Over the year, seniors ﬁlled 33,800 sidenaﬁl
prescriptions (mail order and retail) representing 242,552 pills.
The average PSMPM cost for sidenaﬁl was $0.39 compared 
with $9.52 for PPI’s and $1.35 for antihistamines. CONCLU-
SIONS: The prevalence of treated ED patients in a senior
managed care population is 60% higher than that of younger
members ages 18–64. The cost of sidenaﬁl use in senior males is
relatively low.
PIH17
EVALUATION OF TADALAFIL AND VARDENAFIL TREATMENT
PATTERNS IN PRIOR SILDENAFIL USERS
Harnett J1, McLaughlin T2, Burhani S2, Scott B3
1Pﬁzer Inc, New York, NY, USA; 2NDC Health, Phoenix, AZ, USA;
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OBJECTIVES: Among currently available oral PDE-5 agents,
sildenaﬁl remains the most commonly used ED therapy. We eval-
uated reﬁll rates and costs in sildenaﬁl users who tried a com-
petitor using a claims database. METHODS: Males 18+ years
old newly initiated on sildenaﬁl were identiﬁed in NDCHealth’s
Intelligent Health Repository. Patients had at least 6 months
history prior to through 6 months following initial claim for
sildenaﬁl. Treatment patterns following switch to competitors
and resource utilization in patients who switched vs. those who
did not switch were evaluated. RESULTS: About 6% of the
